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Journal of Stroke and CBackground: The aim of this nationwide, prospective registry of acute cerebral large-
vessel occlusion was to assess the efficacy of endovascular treatment (EVT) on
outcome in the ‘‘real-world’’ settings. Methods: Medical information of the patients
was anonymized and registered prospectively through a Web site from 84 medical
centers in Japan. Reperfusion of the affected arteries was evaluated by the Throm-
bolysis in Cerebral Infarction grade on cerebral angiography or by the modified
Mori grade on magnetic resonance angiography. Clinical outcome was evaluated
by modified Rankin Scale (mRS) at 90 days after onset. Symptomatic intracranial
hemorrhage and procedure-related complications were also analyzed. Results:
Among intravenous tissue plasminogen activator (IV t-PA)–failed patients, no sig-
nificant difference in favorable outcome was seen with or without EVT overall
(41.7% versus 36.8%, P 5 .55). However, EVT significantly increased favorable out-
comes (mRS score 0-2) in patients with internal carotid artery (ICA)/middle cerebral
artery M1/basilar artery (BA) occlusion (41.3% versus 20.5%, P 5 .019). In contrast,
among t-PA–ineligible patients, EVT significantly increased favorable outcomes
overall (29.1% versus 19.5%; odds ratio, 1.70; P5 .007). Furthermore, favorable out-
comes were more common in patients with ICA/M1/BA occlusion (29.0% versus
10.3%; odds ratio, 3.56; P , .0001). Multivariate analysis also confirmed the efficacy
of IV t-PA, EVT, and their combination for favorable outcome. Conclusions: EVT
significantly improved clinical outcomes in IV t-PA–failed and t-PA–ineligible pa-
tients with ICA/M1/BA occlusion. These findings support the introduction of
EVT for acute proximal artery occlusion. Key Words: Acute stroke—large-vessel
occlusion—endovascular treatment—tissue plasminogen activator—national
registry.
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S. YOSHIMURA ET AL.1184Introduction
Although the introduction of intravenous (IV) adminis-
tration of recombinant tissue plasminogen activator
(t-PA) has had a significant impact on the treatment of
acute stroke, problems with its use have become
apparent. For example, IV t-PA is reportedly used in
less than 5% of all ischemic stroke cases, and the rate
of early recanalization of the affected artery, which re-
portedly correlates with better clinical outcomes, appears
low.1-3 The rate of recanalization is known to be higher
with intra-arterial (IA) treatments, such as thrombolysis
and mechanical procedures than with IV t-PA.2 End-
ovascular treatment (EVT), such as mechanical thrombec-
tomy, balloon angioplasty, or thrombolysis, has been
associated with higher rate of reperfusion,4-10 but recent
randomized, controlled trials have failed to confirm its
clinical efficacy compared with IV t-PA or standard
care.11-13
As the first nationwide, prospective registry of acute ce-
rebral large-vessel occlusion, this study was conducted to
assess the impact of EVT on clinical outcome following
approval of a mechanical clot retriever in Japan.
Methods
The registry covered all patients with acute stroke
because of large-vessel occlusion who were admitted to
84 participatingmedical centers within 24 hours after onset
between July 1, 2010, and June 30, 2011. Medical informa-
tion of the patients was anonymized and registered pro-
spectively through a Web site (http://www.rescue-japan.
jp). Factors related to treatment selection and outcomes
were investigated as follows: time to admission, type of
stroke, occluded vessel, National Institutes of Health
Stroke Scale (NIHSS) score on admission, modified Rankin
scale (mRS) score 3 months after onset, and treatments
including various devices for EVT, medications, and labo-
ratory data. The methods, results, and complications of
EVT were precisely recorded. The study was approved
by the local institutional review committee in each hospi-
tal, and its protocol was registered (University Hospital
Medical Information Network: UMIN000003412). The reg-
ister of patients was monitored to rule out selection bias by
monitoring committee.
Primary and Secondary Outcomes
The primary outcome was the rate of an mRS score of
0-2 at 90 days after onset. Secondary outcomes were (1)
recanalization of the target vessel (immediately after
treatment and 24 hours after onset), (2) rate of an mRS
score of 0-1 at 90 days after onset, (3) NIHSS score on
admission and 7 days after onset, (4) relationship between
recanalization and prognosis, (5) symptomatic intracra-
nial hemorrhage within 24 hours after onset, (6) death
within 90 days after onset, and (7) other adverse events.Neurologic Evaluation
NIHSS score was evaluated on admission, 1 hour after
bolus injection of t-PA, immediately after EVT, 24 (68)
hours after onset, and 7 (62) days after onset.Computed Tomography and Magnetic Resonance
Imaging
All patients underwent repeated computed tomogra-
phy (CT) or magnetic resonance imaging (MRI) with
MR angiography at 24 (68) hours after onset, except for
patients admitted 16-24 hours after onset.Intravenous Tissue Plasminogen Activator
IV t-PAwas performed as the first-line treatment within
3 hours of symptom onset, in accordance with the stan-
dard protocol in Japan (.6 mg/kg dose, 10% bolus, 90%
continuously infused over 60 minutes).14Endovascular Treatment
EVT was performed basically IV t-PA–failed or t-PA–
ineligible patients within 8 hours after onset. EVT was
defined as IA catheter procedures such as clot removal/
aspiration, balloon angioplasty, stenting, and IA throm-
bolysis using a microcatheter.Reperfusion Analysis
Neuroimaging studies at baseline with CT or MR angi-
ography were performed for proving large arterial occlu-
sion. When IV t-PA was performed, reperfusion of the
affected artery was evaluated on cerebral angiography
or MR angiography at 1-3 hours after t-PA bolus injection
and at 24 (68) hours after onset. In cases of EVT, reperfu-
sion of the affected artery was evaluated on final angiog-
raphy and on MR angiography at 24 (68) hours after
onset.
On cerebral angiography, reperfusion was classified
according to the modified Thrombolysis in Cerebral
Infarction (TICI) grade.15 Grade 0, no perfusion; grade
1, perfusion past the initial obstruction, but limited distal
branch filling with little or slow distal perfusion; grade 2,
penetration with minimal perfusion; grade 2A, perfusion
of less than half of the vascular distribution of the
occluded artery; grade 2B, perfusion of half or greater of
the vascular distribution of the occluded artery; and
grade 3, full perfusion with filling of all distal branches.
On MR angiography, reperfusion was evaluated ac-
cording to the modified Mori grade.16 Grade 0, no reper-
fusion; grade 1, movement of thrombus not associated
with any flow improvement; grade 2, partial (branch)
recanalization in less than 50% of the branches in the
occluded arterial territory; and grade 3, nearly complete
recanalization with reperfusion in .50% of the branches
in the occluded arterial territory.
Figure 1. Flowchart of patients. Abbrevia-
tions: EVT, endovascular treatment; IV t-PA,
intravenous tissue plasminogen activator;
NIHSS, National Institutes of Health Stroke
Scale.
EFFICACY OF ENDOVASCULAR TREATMENT FOR ACUTE STROKE 1185Successful reperfusion in this study was defined as
grades 2B and 3 using TICI grading or grade 3 using
modified Mori’s grading.
IV t-PA–failed patients were defined as those patients
whose vessel was not significantly reperfused, that is,
showing modified Mori’s grade 0-1 on MR angiography
or TICI grade 0-1 on cerebral angiography at 1-3 hours af-
ter the bolus injection of t-PA.
Evaluation of Clinical Outcome
Patient outcomes were evaluated using the mRS on
admission and 90 (610) days after onset. A favorable
outcome was defined as an mRS score of 0-2.
Evaluation of Symptomatic Hemorrhage
In this study, intracranial hemorrhage within 24 6
8 hours after onset was evaluated on follow-up imaging.
Symptomatic hemorrhage was defined according to
the Safe Implementation of Thrombolysis in Stroke-
Monitoring Study definition,17 local or remote paren-
chymal hematoma type 2 on follow-up imaging, plus
neurologic deterioration, as indicated by a score on the
NIHSS that was higher by 4 points or more than the base-
line value or lowest value between baseline and 24 hours
or hemorrhage leading to death.
Statistical Analysis
Statistical analysis was performed using commercially
available software (JMP 7; SAS Institute, Cary, NC). The
statistical significance of intergroup differences was
assessed using the t test for quantitative scales, Pearson
c2 test for categorical scales, and the Mann–Whitney
U test or Wilcoxon signed-rank test for ordinal scales.
Values of P less than .05 were considered significant.
Statistical analysis was carried out by members of the
writing committee.Results
Backgrounds and Characteristics of Patients
Of the 1454 registered patients, 1442 patients (99.2%)
met the inclusion criteria and were analyzed in this study
(Fig 1, Table 1). Median baseline NIHSS score on admis-
sion was 16 (interquartile range, 9-21), and median time
from onset to admission was 125 minutes (interquartile
range, 60-300 minutes). In this study, 849 patients
(58.9%) arrived within 3 hours and 312 patients (21.6%)
arrived 3-8 hours after onset.
Cardioembolic infarction was diagnosed in 1023 pa-
tients (71.0%), and atherothrombotic infarction was diag-
nosed in 288 (20.0%). The occluded vessel was the internal
carotid artery (ICA) in 407 patients (28.2%), the MCA in
760 (52.7%), the basilar artery (BA) in 99 (6.9%), and mul-
tiple in 57 patients (4.0%).
Reperfusion after IV t-PA and Clinical Outcome
In the 449 patients who received IV t-PA, 318 under-
went a reperfusion study: 147 patients (46.2%) underwent
cerebral angiography alone, 119 patients (37.4%) under-
went repeated MR angiography alone, and 52 patients
underwent both (16.3%).
On cerebral angiography, reperfusion was judged
1-3 hours after IV t-PA by the TICI grade.15 Successful re-
perfusion, defined as grade 2B or 3, was obtained in 11%
of ICA cases, 29.2% of proximal M1 cases, 37.8% of distal
M1 cases, 40.7% of M2 or distal cases, and 23.6% of BA
cases (Fig 2).
Clinical outcomes of patients were also analyzed by
location of vessel occlusion (Table 2). Overall, a signif-
icant difference in the rate of successful reperfusion
was evident between patients treated by IV t-PA alone
and IV t-PA 1 EVT (43.5% versus 62.8%, OR 2.19,
P 5 .006), but clinical outcome showed no significant
difference (42.2% versus 44.5%, OR 1.09, P 5 .65). In
Table 1. Baseline characteristics of patients
Median (IQR) or n (%)
Total number of munched
patients
1442
Mean age, y 75.5 (67-83)
Sex, female 634 (44.0)
Hypertension 818 (56.7)
Diabetes mellitus 282 (19.6)
Hyperlipidemia 283 (19.6)
Atrial fibrillation 853 (59.2)
Congestive heart failure 170 (11.8)
Smoking 203 (14.1)
Systolic BP, mm Hg 157 (139-174)
Diastolic BP, mm Hg 84 (72-97)
Serum glucose, mg/dL 127 (109-154.5)
Baseline NIHSS score 16 (9-21)
Onset to admission, min 125 (60-300)
Within 3 h 849 (58.9)
3-8 h 312 (21.6)
More than 8 h 192 (13.3)
Unknown 89 (6.2)
Stroke subtype
Cardioembolic infarction 1023 (71.0)
Atherothrombotic infarction 288 (20.0)
Others/unclassified 131 (9.1)
Occluded vessel
ICA 407 (28.2)
Extracranial ICA 195 (13.5)
Intracranial ICA 186 (12.9)
ICA (unknown) 26 (1.8)
MCA 760 (52.7)
Proximal M1 263 (18.2)
Distal M1 223 (15.5)
M1 (unknown) 5 (.3)
M2 or distal 269 (18.7)
BA 99 (6.9)
PCA 52 (3.6)
VA 32 (2.2)
ACA 17 (1.2)
Multiple 57 (4.0)
Others 104 (7.2)
Unknown 15 (1.0)
Abbreviations: ACA, anterior cerebral artery; BA, basilar artery;
BP, blood pressure; ICA, internal carotid artery; IQR, interquartile
range; M1, middle cerebral artery M1 portion; MCA, middle cere-
bral artery; NIHSS, National Institutes of Health Stroke Scale;
PCA, posterior cerebral artery.
Figure 2. Reperfusion of the affected arteries on cerebral angiography after
intravenous tissue plasminogen activator. Reperfusion of the affected arteries
was evaluated by the TICI grade on cerebral angiography; grade 0, no perfu-
sion; grade 1, perfusion past the initial obstruction but limited distal branch
filling with little or slow distal perfusion; grade 2, penetration with minimal
perfusion; grade 2A, perfusion of less than half of the vascular distribution of
the occluded artery; grade 2B, perfusion of half or greater of the vascular
distribution of the occluded artery; and grade 3, full perfusion with filling
of all distal branches. Successful reperfusion, defined as grade 2B or 3, was
obtained in 11% of ICA cases, 29.2% of proximal M1 portion of middle ce-
rebral artery cases, 37.8% of distal M1 cases, 40.7% of M2 or distal cases,
and 23.6% of BA cases. Abbreviations: BA, basilar artery; ICA, internal ca-
rotid artery; TICI, Thrombolysis in Cerebral Infarction.
S. YOSHIMURA ET AL.1186the ICA, successful reperfusion and favorable outcome
(mRS score 0-2) were more common after IV t-
PA 1 EVT than after IV t-PA alone (reperfusion:
56.0% versus 18.8%, OR 5.51, P 5 .0006; favorable
outcome: 43.8% versus 21.4%, OR 2.85, P 5 .015). How-
ever, other vessels such as the M1 and BA showed no
significant differences in rate of successful reperfusion
or favorable outcome.Effect of EVT for IV t-PA–Failed Patients
Next, the effect of EVT for IV t-PA–failed patients was
analyzed. Of the 168 IV t-PA-failed patients, 110 were
treated with EVT. The EVT group was younger (71.5
versus 76 years, P 5 .024) and contained fewer patients
with hypertension (52.7% versus 69%, P 5 .041), but
neurologic grade was significantly worse (median NIHSS
score: 17 versus 14, P 5 .0019). Median duration to EVT
was 210 minutes (range, 180-245 minutes) after onset.
A difference was seen in the rate of successful reperfu-
sion (88.3% versus 42.0%, P , .0001, Table 3), but no sig-
nificant difference in favorable outcome was seen
between patients with or without EVT overall (41.7%
versus 36.8%, P 5 .55). EVT significantly increased favor-
able outcomes (mRS score 0-2) in patients with ICA/M1/
BA occlusion (41.3% versus 20.5%, P5 .019, Table 3, Fig 3,
A). These results suggest that EVTwas effective to obtain
better clinical outcomes for IV t-PA–failed patients with
ICA/M1/BA occlusion.Effect of EVT for IV t-PA–Ineligible Patients
The effect of EVT for IV t-PA–ineligible patients was
then evaluated. Among 993 patients who did not undergo
IV t-PA, 636 patients with NIHSS score of 4 or more and
arrived within 8 hours after onset were judged as candi-
dates for EVT (Fig 1). Among these 636 patients, 220
were treated with EVT. The EVT group was significantly
younger (73 versus 78 years, P , .0001) and included
fewer women (37.7% versus 50.2%, P 5 .0025), although
Table 2. Analysis of reperfusion and outcome by location of vessel occlusion
Reperfusion analysis (n 5 318) Outcome analysis (n 5 442)
Successful reperfusion*, n (%) OR (95% CI) P Favorable outcomey, n (%) OR (95% CI) P
Total 167 (52.5%) 190 (43.0%)
IV t-PA alone 74 (43.5%) 2.19 (1.40-3.46) .006 125 (42.2%) 1.09 (.74-1.64) .65
IV t-PA 1 EVT 93 (62.8%) 65 (44.5%)
ICA 34 (41.5%) 33 (31.7%)
IV t-PA alone 6 (18.8%) 5.51 (2.03-17.0) .0006 12 (21.4%) 2.85 (1.23-6.87) .015
IV t-PA 1 EVT 28 (56.0%) 21 (43.8%)
M1 73 (58.6%) 70 (39.3%)
IV t-PA alone 36 (51.4%) 1.40 (.70-2.81) .34 42 (36.2%) 1.45 (.77-2.72) .25
IV t-PA 1 EVT 37 (59.7%) 28 (45.2%)
BA 19 (79.2) 13 (43.3)
IV t-PA alone 7 (70.0) 2.57 (.35-23.4) .35 7 (43.8) .96 (.22-4.15) .96
IV t-PA 1 EVT 12 (85.7) 6 (42.9)
Others 64 (50.8%) 106 (54.6%)
IV t-PA alone 42 (47.7%) 1.51 (.70-3.28) .29 88 (56.4%) .70 (.34-1.42) .32
IV t-PA 1 EVT 22 (57.9%) 18 (47.4%)
Abbreviations: EVT, endovascular treatment; IV t-PA, intravenous tissue plasminogen activator; M1, middle cerebral artery M1 portion; OR,
odds ratio; CI, confidence interval.
*Successful reperfusion, Thrombolysis in Cerebral Infarction grades 2B and 3 or modified Mori’s grade 3.
yFavorable outcome, modified Rankin Scale score 0-2 at 90 days after onset.
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P5 .52). Median duration to EVTwas 240 minutes (range,
179-346 minutes) after onset.
Against this background, EVT increased the rates of
successful reperfusion (78.5% versus 44.5%, OR 4.54,
P , .0001, Table 3) and favorable outcomes (29.1% versus
19.5%, OR 1.70, P 5 .007). Furthermore, favorable out-
comes were more common in patients with ICA/M1/BA
occlusion (29.0% versus 10.3%, OR 3.56, P, .0001, Fig 3, B).
These results suggest that EVTwas effective for obtain-
ing better clinical outcomes in IV t-PA–ineligible patients,
particularly when the occlusion involved proximal ar-
teries.Table 3. Analysis of reperfusion and outcome in
IV t-PA–failed patients With EVT (n 5 110) W
Successful reperfusion 68/77 (88.3)
Favorable outcome
Overall 45/108 (41.7)
ICA/M1/BA occlusion 38/92 (41.3)
IV t-PA–ineligible patients With EVT (n 5 220) Wi
Successful reperfusion* 135/172 (78.5)
Favorable outcomey
Overall 64/220 (29.1)
ICA/M1/BA occlusion 51/176 (29.0)
Abbreviations: BA, basilar artery; CI, confidence interval; EVT, endov
artery M1 portion; OR, odds ratio.
*Successful reperfusion, Thrombolysis in Cerebral Infarction grades 2B
yFavorable outcome, modified Rankin Scale score 0-2 at 90 days afterSymptomatic Intracranial Hemorrhage
Of the 1360 patients who underwent repeated CT or
MRI at 246 8 hours after onset, symptomatic hemorrhage
was observed in 46 (3.4%) overall, comprising 13 of 644
patients (2.0%) in the conservative group treated without
IV t-PA or EVT, 11 of 292 patients (3.8%) with IV t-PA, 8 of
148 patients (5.4%) with IV t-PA and EVT, and 13 of 264
patients (4.9%) with EVT only. The rate of symptomatic
intracranial hemorrhage (sICH) in patients treated with
IV t-PA alone was comparable with that seen in the Japa-
nese postmarketing trial of alteplase.16 No significant
increase in sICH was observed in either the IV t-PAIV t-PA–failed or t-PA–ineligible patients
ithout EVT (n 5 58) P OR (95% CI)
21/50 (42.0) ,.0001 10.4 (4.42-26.7)
21/57 (36.8) .55 1.22 (0.64-2.39)
8/39 (20.5) .019 2.73 (1.17-6.96)
thout EVT (n 5 416) P OR (95% CI)
110/247 (44.5) ,.0001 4.54 (2.94-7.14)
80/410 (19.5) .007 1.70 (1.16-2.48)
29/282 (10.3) ,.0001 3.56 (2.17-5.95)
ascular treatment; ICA, internal carotid artery; M1, middle cerebral
and 3 or modified Mori’s grade 3.
onset.
Figure 3. Functional outcome at 90 days in the patients with ICA/M1/BA
occlusion. (A) Functional outcome at 90 days in the IV t-PA–failed patients
with or without EVT. Shown are 90-day mRS scores in patients undergoing
additional EVTor receiving standard medical care for the IV t-PA–failed pa-
tients with ICA/M1/BA occlusion. The percentages of patients are shown in,
above, or below each cell. Additional EVTwas superior to standard medical
care in IV t-PA–failed patients with ICA/M1/BA occlusion (P 5 .019). (B)
Functional outcome at 90 days in the IV t-PA–ineligible patients with or
without EVT. EVT was superior to standard care in IV t-PA–ineligible pa-
tients with ICA/M1/BA occlusion (P , .0001). Abbreviations: BA, basilar
artery; EVT, endovascular treatment; ICA, internal carotid artery; IV t-
PA, intravenous tissue plasminogen activator; mRS, modified Rankin Scale.
Table 4. Characteristics associated with favorable outcome
at 90 d
Characteristic P OR (95% CI)
Baseline NIHSS, per
1-point increase
,.0001 .876 (.858-.894)
Age, per 1-y increase ,.0001 .963 (.951-.975)
Sex, male (0) vs
female (1)
.534 .914 (.688-1.214)
IV t-PA 1 EVT ,.0001 3.244 (2.055-5.120)
IV t-PA alone ,.0001 2.971 (2.097-4.209)
EVT alone .007 1.699 (1.156-2.498)
Abbreviations: NIHSS, National Institutes of Health Stroke Scale.
S. YOSHIMURA ET AL.1188and EVT group or EVT-alone group comparedwith the IV
t-PA group (P 5 .42 and P 5 .50, respectively).Procedure-Related Complications after EVT
Procedure-related complications were observed in 32 of
268 procedures (11.9%) in the EVT-alone group, of which
9 (3.4%) were clinically significant. On the other hand,
procedure-related complications were seen with 16 of
148 procedures (10.8%) in the IV t-PA and EVT group,
of which 4 (2.7%) were clinically significant. There was
no significant difference between the EVT-alone group
and IV t-PA and EVT group.Characteristics for Favorable Outcome at 90 Days
Multivariate regression analysis indicated that higher
baseline NIHSS and higher age were significantly related
to unfavorable outcome, whereas IV t-PA1 EVT, IV t-PA,
and EVT were all associated with favorable outcome
significantly (Table 4). Odds ratio was highest in combina-
tion with IV t-PA 1 EVT, IV t-PA alone, and EVT alone in
order.Discussion
In this nationwide registry study of acute large-vessel
occlusion, EVT significantly increased the rate of favor-
able outcomes in patients with ICA occlusion but not
with other vessel occlusion. Among IV t-PA–failed
patients, EVT increased the rate of favorable outcomes
in patients with ICA/M1/BA occlusion but not overall.
In contrast, among IV t-PA–ineligible patients, EVT
increased the rate of favorable outcomes regardless of
the affected vessels, and favorable outcomes were more
common in patients with ICA/M1/BA occlusion. The
reason for better outcomes involving these proximal ves-
sels might be that catheter interventions were feasible,
and successful reperfusion by IV t-PA alone was rare. In
fact, a significant increase in successful reperfusion was
seen with addition of EVT in both IV t-PA–failed and
t-PA–ineligible patients with ICA/M1/BA. Patient selec-
tion based on preprocedural vessel imaging is thus key
to obtain a favorable effect with EVT.
On the other hand, recent randomized, controlled trials
failed to show the efficacy of EVT for acute stroke.11-13 For
example, the Interventional Management of Stroke III
trial was performed to determine whether a combined
approach with IV t-PA and EVT is more effective than
IV t-PA alone. However, that trial did not show any
benefit in terms of functional outcome from the use of
EVT.11 The Synthesis Expansion and the Mechanical
Retrieval and Recanalization of Stroke Clots Using Embo-
lectomy (MR RESCUE) trial likewise failed to show any
efficacy of EVT.12,13 The failure of these trials might
be attributable to delayed initiation of EVT and/or
insufficient reperfusion using first-generation devices. In
this registry, EVT was started much earlier (210 minutes
after onset in RESCUE-Japan versus more than 360 mi-
nutes in MR RESCUE), and the reperfusion rate was
much higher than that of MR RESCUE (TICI IIb-III:
52.5% in RESCUE-Japan versus 26% in MR RESCUE).13
The reason for the higher rate of reperfusion in the
present study might be because of unlimited use of en-
dovascular devices such as stents and balloons. These
EFFICACY OF ENDOVASCULAR TREATMENT FOR ACUTE STROKE 1189differences should be considered when designing future
comparative studies.
The disadvantages of EVTalso need to be kept in mind.
For example, the device may injure the vessel, resulting in
intracranial hemorrhage or infarction. The incidence of
clinically significant procedure-related complications
was 3.4% with EVT alone and 2.8% with IV t-PA and
EVT in the present study, comparable with the 5.5% in
the Multi MERCI trial.8 Furthermore, symptomatic hem-
orrhage was not significantly elevated by EVT after IV
t-PA in this study. The incidence of complications with
current EVT, thus, seems acceptable.
This study had some limitations. In this study, baseline
characteristics were not balanced because the study was
not a randomized trial. Also, treatment selection was
made in each institute independently, which might have
affected the clinical outcomes. To clarify the real clinical
impact of EVT for acute stroke, randomized trials
applying new-generation devices such as stent retrievers
with appropriate patient selection using vessel imaging
should be performed in the near future.
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